4 Perspectives On What’s Next In Clinical Trial Tech
From the article:
“The integration of AI in clinical trials extends beyond target discovery, ushering in a paradigm shift essential to advancing clinical trials in 2025 and beyond. A biology-first approach to AI plays a pivotal role in addressing challenges and unlocking efficiencies in clinical trials. Unlike generic applications, causal AI models designed to assimilate data from patient biology can provide insights that guide trial design, patient selection, and safety monitoring. By leveraging AI to understand the biological mechanisms behind drug actions, researchers can identify which patients are most likely to respond favorably and tolerate treatment, thereby improving trial outcomes.
“AI-driven analyses can also anticipate potential adverse events and suggest protocol modifications, such as incorporating complementary treatments to mitigate side effects. This informed approach supports the safety and efficacy of trials and can accelerate the path to approval, ultimately benefiting a wider patient population.” –Niven Narain, Ph.D., president and CEO, BPGbio
➡️ For the full article and three other great perspectives, please visit: 4 Perspectives On What’s Next In Clinical Trial Tech
At BPGbio, we use patient biology (we have one of the largest omics-annotated biobanks in the world) and AI to identify biomarkers that help in diagnosing, staging, and following disease processes more effectively.
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
Media Contact:
media@bpgbio.com
